E&C Clears User Fee Bill, Leaves Door Open For LDT, Cosmetics Measures

By Beth Wang / May 18, 2022 at 4:56 PM
The House Energy & Commerce Committee on Wednesday (May 18) passed 55-0 comprehensive user fee legislation that includes new language giving FDA authority to require sponsors of pediatric cancer trials to study a combination of drugs, rather than one drug at a time, in order to speed development of drugs that treat relapsed cancer. E&C leaders signaled they may still add measures to hike FDA’s oversight of cosmetic products and laboratory-developed tests to align with provisions in the Senate health...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.